Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam

Urology

Volumn 68, Issue 3, 2006, Pages 615-620

  van der Cruijsen Koeter, Ingrid W ^a   Roobol, Monique J ^a   Wildhagen, Mark F ^a   van der Kwast, T H ^a   Kirkels, W J ^a   Schröder, Fritz H ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TIME SERIES ANALYSIS; TRANSRECTAL ULTRASONOGRAPHY;

AGED; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 33748938179     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.03.015     Document Type: Article

References (17)

1. de Koning H.J., Liem M.K., Baan C.A., et al. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Study of Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 98 2 (2002) 268-273
2. Auvinen A., Rietbergen J.B.W., Denis L.J., et al. Prospective evaluation plan for randomised trials of prostate cancer screening. J Med Screening 3 (1996) 97-104
3. Tarone R.E., Chu K.C., and Brawley O.W. Implications of stage specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 11 (2000) 167-170
4. Labrie F., Candas B., Dupont A., et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 38 (1999) 83-91
5. Bartsch G., Horninger W., Klocker H., et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58 (2001) 417-424
6. Boer R., and Schröder F.H. Quebec randomized controlled trial on prostate cancer screening shows no evidence of mortality reduction. Prostate 40 (1999) 130-134
7. Hugosson J., Aus G., Lilja H., et al. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 100 7 (2004) 1397-1405
8. Mäkinen T., Tammela T.L.J., Stenman U.H., et al. Second round results of the Finnish population-based prostate cancer screening trial. Clin Cancer Res 10 (2004) 2231-2236
9. Beemsterboer P.M.M., Kranse R., de Koning H.J., et al. Changing role of three screening modalities in the European Randomized Study of Screening for Prostate Cancer (Rotterdam). Int J Cancer 84 (1999) 437-441
10. Schröder F.H., van der Maas P., Beemsterboer P.M.M., et al. Evaluation of digital rectal examination as a screening test for prostate cancer. J Natl Cancer Inst 90 (1998) 1817-1823
11. Rietbergen J.B.W., Boeken Kruger A.E., Hoedemaeker R.F., et al. Repeat screening for prostate cancer after 1-year follow-up in 984 biopsied men: clinical and pathological features of detected cancer. J Urol 160 (1998) 2121-2125
12. van der Cruijsen-Koeter I.W., Vis A.N., Roobol M.J., et al. Comparison of screen detected and clinically diagnosed prostate cancer in the European Randomised Study of Screening for Prostate Cancer, section Rotterdam. J Urol 174 (2005) 121-125
13. Määttänen L., Auvinen A., Stenman U.H., et al. Three-year results of the Finnish Prostate Cancer Screening Trial. J Natl Cancer Inst 93 (2001) 552-553
14. Hugosson J., Aus G., Lilja H., et al. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol 169 5 (2003) 1720-1723
15. Draisma G., and De Koning H.J. MISCAN: estimating lead-time and over-detection by simulation. BJU Int 92 suppl 2 (2003) 106-111
16. Hoedemaeker R.F., van der Kwast T.H., Boer R., et al. Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst 93 (2001) 1153-1158
17. van der Cruijsen-Koeter I.W., van der Kwast T.H., and Schröder F.H. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-section Rotterdam. J Natl Cancer Inst 95 (2003) 1462-1466